Recent discussions on X about Phathom Pharmaceuticals (PHAT) have been buzzing with activity following the release of their Q2 2025 financial results. Posts on the platform highlight the company's significant revenue growth, driven by strong sales of their drug VOQUEZNA, with over 580,000 prescriptions reported. Many users are pointing to the raised revenue guidance for 2025 as a sign of confidence in the company’s trajectory.
The conversation also touches on the competitive landscape, with some drawing comparisons to other pharmaceutical developments in the same therapeutic area. There’s a palpable excitement around the potential for PHAT’s core product to capture a larger market share in the U.S. as gastrointestinal treatments gain traction. This latest earnings report has clearly sparked renewed interest in the stock among online communities.
Note: This discussion summary was generated from an AI condensation of post data.
Phathom Pharmaceuticals Insider Trading Activity
Phathom Pharmaceuticals insiders have traded $PHAT stock on the open market 11 times in the past 6 months. Of those trades, 9 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PHAT stock by insiders over the last 6 months:
- JAMES N TOPPER has made 6 purchases buying 59,403 shares for an estimated $191,988 and 0 sales.
- ASIT PARIKH has made 3 purchases buying 20,000 shares for an estimated $69,184 and 0 sales.
- MOLLY HENDERSON (CFO and CBO) sold 3,678 shares for an estimated $16,739
- ROBERT CHARLES BREEDLOVE (Principal Accounting Officer) sold 1,692 shares for an estimated $14,151
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Phathom Pharmaceuticals Hedge Fund Activity
We have seen 59 institutional investors add shares of Phathom Pharmaceuticals stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 7,042,325 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $67,535,896
- CHECKPOINT CAPITAL L.P. removed 2,274,157 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $14,258,964
- TANG CAPITAL MANAGEMENT LLC added 700,000 shares (+140.0%) to their portfolio in Q1 2025, for an estimated $4,389,000
- DECHENG CAPITAL LLC removed 694,254 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,352,972
- JACOBS LEVY EQUITY MANAGEMENT, INC added 596,108 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,737,597
- AVIDITY PARTNERS MANAGEMENT LP removed 590,100 shares (-42.5%) from their portfolio in Q1 2025, for an estimated $3,699,926
- CITIGROUP INC added 486,282 shares (+1090.9%) to their portfolio in Q1 2025, for an estimated $3,048,988
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Phathom Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $PHAT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Craig-Hallum issued a "Buy" rating on 06/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/09/2025
- Needham issued a "Buy" rating on 06/06/2025
- Guggenheim issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for Phathom Pharmaceuticals, check out Quiver Quantitative's $PHAT forecast page.
Phathom Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $PHAT recently. We have seen 5 analysts offer price targets for $PHAT in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Chase Knickerbocker from Craig-Hallum set a target price of $17.0 on 06/09/2025
- Matthew Caufield from HC Wainwright & Co. set a target price of $20.0 on 06/09/2025
- Joseph Stringer from Needham set a target price of $28.0 on 06/06/2025
- Paul Choi from Goldman Sachs set a target price of $5.0 on 05/02/2025
- Yatin Suneja from Guggenheim set a target price of $12.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
